Hormone In Vitro Research Only

Ipamorelin: The Selective Growth Hormone Peptide & Body Composition Research

0 Cortisol / Prolactin Impact — Uniquely Selective

Ipamorelin is a synthetic pentapeptide and selective Growth Hormone Secretagogue (GHS) that mimics ghrelin by binding GHSR-1a receptors in the anterior pituitary. In a landmark study by Raun et al. at Novo Nordisk, ipamorelin was identified as the most selective GH secretagogue tested — triggering robust GH release with zero measurable effect on cortisol, ACTH, or prolactin. This selectivity profile distinguishes it from all other GHRPs studied to date.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

⚗️

GHSR-1a Receptor Agonism

Binds ghrelin receptors in the anterior pituitary to trigger pulsatile, physiologically-timed GH release that mirrors natural young-adult secretion patterns.

🛡️

HPA Axis Independence

Unlike GHRP-2 and GHRP-6, ipamorelin does not activate the HPA axis — producing no cortisol, ACTH, or prolactin elevation even at high doses.

🧬

Pulsatile GH Preservation

Induces pulsatile (not continuous) GH release, preserving natural GH rhythms and avoiding the receptor desensitisation seen with continuous GH secretagogues.

📊

IGF-1 Downstream Upregulation

GH released by ipamorelin signals hepatic IGF-1 production, driving downstream anabolic, recovery-promoting, and metabolic effects.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

🔬

Cortisol Elevation

Raun et al. Novo Nordisk (1998)

💊

Phase IIb

Human Clinical Trial

Helsinn Therapeutics — GI motility

🦴

+12wk

Bone Density Increase

Ovariectomised rat model

⚗️

Amino Acids

Synthetic pentapeptide

Selectivity Profile — GH Secretagogue Hormonal Impact Comparison

GH Release

100

Cortisol Impact

Prolactin Impact

ACTH Impact

IGF-1 Increase

Comparative data from Raun et al. (1998) Endocrinology. Ipamorelin vs. GHRP-2 selectivity profile. In vitro / preclinical data.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

93%

Tolerability

Low Severity

22%

Water Retention

Low Severity

15%

Mild Hunger Increase

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.